Gilead Sciences Inc (GILD) Q4 2021 (USD): Adj. EPS 0.69 (exp. 1.59), Revenue 7.20bln (exp. 6.66bln)

• Adj. product GM 70.5%.
• Veklury revenue 1.36bln (exp. 0.79bln).
• Trodelvy revenue 118mln (exp. 120mln). 

GUIDANCE

• FY adj. EPS view 6.20-6.70 (exp. 6.89), revenue view 7.24bln (exp. 24.37bln). 
• Product sales view 23.8-24.3bln. 
• Veklury revenue view 2bln (exp. 1.52bln) 

NEWS

• GlaxoSmihKline (GSK LN) announced a settlement between Viiv healthcare and Gilead (GILD) that resolves litigation relating to Biktarvy and VIIV's Dolutegravir patents and entry into a patent licence agreement.
• GILD will make an up front payment of USD 1.25bln to VIIV in Q1 22 and a 3% royalty on future US sales of Biktarvy. 

Via businesswire